The Day After...

Ironwood's IPO did not turn out exactly as planned when the company did not quite reach the price per share amount for which it was hoping. This could could put the brakes on any pending IPOs in the biotech world as they wait and see what happens to Ironwood. Best care scenario is that investors were just tentative and did not jump in on stock at the first call, but will come around in a few weeks. Worst case scenario is that investors are still scarred by the financial happenings over the past year and won't budge. Either way, Ironwood will have to wait and see what goes down.

Read more here in Xconomy

Next, the Canadian company Labopharm scored a FDA approval today for its once daily version of trazodone. The approval is good for the manufacturer, but I wonder just how big the market is going to be for this drug. Trazodone is not a new medication, and in the anti-depressant world it faces stiff competition from other, newer meds. Nevertheless, somebody will use it as sales are projected in the $30-$40 million range.

Read more here fromhttp://www.reuters.com/article/idUSN0313639620100203

It's not secret that a battle is brewing over legislation on how to protect the intellectual property of biologics. Well, Teva is moving forward with a biosimilar for a populat Amgen drug, Neupogen, and it hopes to get FDA approval to produce and market the product. How will Teva go about this with no real biosimilar regulations in place? The answer is that Teva is treating its drug as a entirely new product with a new BLA...interesting idea. If the FDA looks favorably on this new biologic, expect Teva to pull in some serious cash.

Fierce Biotech reports on the situation here


Last, but not least: Seeking Alpha published a nice blog on the differences between Eli Lilly's new R&D program and GSK's program. Both have their advantages, but I'll let you decide which one you like better!

Seeking Alpha Blog